Singular Genomics Systems, Inc.: capital expenditure payments
Capital expenditure payments for Singular Genomics Systems, Inc. Inspect selected reporting periods, original units and SEC filing links; download the financial history.
All Singular Genomics Systems, Inc. financial histories
What this measure means
Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.
Exact concept: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value covers an annual-duration reporting interval, shown with both start and end dates. Different units remain separate; no currency conversion or interpolation is applied.
Coverage of this history
Selected reporting periods run from 2020-01-01 to 2023-12-31. The SEC response was captured on 2026-09-21.
This selected history ends more than two years before capture. Do not treat its final value as a current balance or current annual result. More recent filings may use another accounting tag; inspect the filings before drawing conclusions about the company.
Selected filing history
| Period start | Period end | Value | Unit | Filed | Source filing |
|---|---|---|---|---|---|
| 2023-01-01 | 2023-12-31 | 970,000 | USD | 2024-03-18 | 10-K · 0000950170-24-032829 |
| 2022-01-01 | 2022-12-31 | 6,022,000 | USD | 2024-03-18 | 10-K · 0000950170-24-032829 |
| 2021-01-01 | 2021-12-31 | 4,864,000 | USD | 2023-03-02 | 10-K · 0000950170-23-005819 |
| 2020-01-01 | 2020-12-31 | 1,380,000 | USD | 2022-03-14 | 10-K · 0000950170-22-003570 |
Related financial histories
- Singular Genomics Systems, Inc.: total assets
- Singular Genomics Systems, Inc.: total liabilities
- Singular Genomics Systems, Inc.: stockholders equity
- Singular Genomics Systems, Inc.: cash and cash equivalents
- Singular Genomics Systems, Inc.: net income or loss
- Singular Genomics Systems, Inc.: operating cash flow
- Singular Genomics Systems, Inc.: revenue
- Singular Genomics Systems, Inc.: financing cash flow
- Singular Genomics Systems, Inc.: investing cash flow
- Singular Genomics Systems, Inc.: retained earnings or deficit
- Singular Genomics Systems, Inc.: basic weighted-average shares
- Singular Genomics Systems, Inc.: diluted weighted-average shares
- Singular Genomics Systems, Inc.: basic earnings per share
- Singular Genomics Systems, Inc.: diluted earnings per share
- Singular Genomics Systems, Inc.: net property, plant and equipment
- Singular Genomics Systems, Inc.: share-based compensation expense
- Singular Genomics Systems, Inc.: operating income or loss
- Singular Genomics Systems, Inc.: current assets
- Singular Genomics Systems, Inc.: interest expense
- Singular Genomics Systems, Inc.: current liabilities
- Singular Genomics Systems, Inc.: current accounts payable
- Singular Genomics Systems, Inc.: operating expenses
- Singular Genomics Systems, Inc.: net inventory
- Singular Genomics Systems, Inc.: gross profit
- Singular Genomics Systems, Inc.: cost of revenue
- Singular Genomics Systems, Inc.: selling, general and administrative expense
- Singular Genomics Systems, Inc.: research and development expense
Inspect the source
- Entity
- Singular Genomics Systems, Inc. / CIK 0001850906
- Captured
- 2026-09-21T17:38:24.417Z
- SEC response SHA-256
96c94e19632c525e3cb8b2505a8fa3d4d734dffbdc567459f97bec91ce25fac7
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001850906.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))